Evernest Financial Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.51M Buy
6,010
+138
+2% +$29.7K 0.32% 51
2026
Q1
$1.16M Buy
5,872
+235
+4% +$52.1K 0.24% 64
2025
Q4
$1.26M Sell
5,637
-334
-6% -$76.1K 0.26% 61
2025
Q3
$1.38M Sell
5,971
-2
-0% -$407 0.39% 49
2025
Q2
$1.11M Buy
5,973
+389
+7% +$72.3K 0.36% 60
2025
Q1
$1.17M Buy
5,584
+229
+4% +$44.5K 0.42% 52
2024
Q4
$952K Buy
5,355
+4,003
+296% +$736K 0.25% 69
2024
Q3
$267K Buy
+1,352
New +$252K 0.07% 137

Other funds holding ABBV

Evernest Financial Advisors's ABBV Position: Q2 2026 in Review

Evernest Financial Advisors increased its AbbVie (ABBV) stake by 2.4% in Q2 2026, buying an estimated $29.7K and bringing the position to 6,010 shares worth $1.51M. The position accounts for 0.32% of the portfolio, ranked #51.

Evernest Financial Advisors first reported a position in ABBV in Q3 2024 and has held it in 8 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Evernest Financial Advisors held 6,010 shares of AbbVie worth $1.51M as of Q2 2026.
  • Evernest Financial Advisors bought 138 AbbVie shares in Q2 2026, an estimated $29.7K.
  • AbbVie made up 0.32% of Evernest Financial Advisors's portfolio in Q2 2026, its #51 holding.
  • Evernest Financial Advisors first reported a position in AbbVie in Q3 2024 and has held it in 8 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Evernest Financial Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.